KLOW (80mg)
$199.99
KLOW is BioRhex’s proprietary recovery research blend combining four complementary peptides in a single compound: BPC-157 (gastric-derived pentadecapeptide), TB-500 (Thymosin Beta-4 active fragment), KPV (alpha-MSH C-terminal tripeptide), and GHK-Cu (copper-binding tripeptide). In research settings, KLOW is studied as a multi-pathway approach to tissue repair signaling, inflammatory modulation, and cellular recovery mechanism research.
BioRhex supplies KLOW as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- COA-verified
- In stock
- ≥99% purity.
- USA manufactured.
What Is KLOW?
KLOW is BioRhex’s proprietary recovery research blend combining four complementary peptides in a single compound: BPC-157 (gastric-derived pentadecapeptide), TB-500 (Thymosin Beta-4 active fragment), KPV (alpha-MSH C-terminal tripeptide), and GHK-Cu (copper-binding tripeptide). In research settings, KLOW is studied as a multi-pathway approach to tissue repair signaling, inflammatory modulation, and cellular recovery mechanism research.
BioRhex supplies KLOW as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Compound Overview
KLOW is a four-peptide research blend studied for its multi-mechanism interactions with tissue biology pathways. Preclinical research models examine how KLOW components may influence:
• BPC-157: Angiogenesis signaling, VEGF pathway interactions, and gastrointestinal mucosal biology research
• TB-500: Actin sequestration, cell migration signaling, and vascular endothelial pathway modulation
• KPV: Anti-inflammatory cytokine signaling and NF-κB pathway modulation research
• GHK-Cu: Collagen synthesis pathways, ECM remodeling, and fibroblast activation signaling
• Combined pathway dynamics: Multi-receptor signaling interactions of simultaneous peptide activity in tissue research models
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.
History of KLOW
KLOW was developed by BioRhex to provide a single, precisely formulated multi-peptide research compound for studying complementary tissue repair pathway interactions. Each of the four components has an independent research history across decades of preclinical investigation.
BPC-157’s tissue signaling properties were characterized at the University of Zagreb. TB-500 derived from research into Thymosin Beta-4’s role in actin cytoskeletal biology. KPV emerged from melanocortin receptor C-terminal fragment research. GHK-Cu was first identified in plasma biology research by Loren Pickart in 1973.
KLOW represents BioRhex’s approach to supplying research-grade precision blends for studying complex, multi-pathway biological interactions in controlled laboratory environments.
Molecular Structure
Proprietary blend: BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) + TB-500 (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-NH₂) + KPV (Lys-Pro-Val) + GHK-Cu (Gly-His-Lys · Cu²⁺)
Research Findings
Published and preclinical research on KLOW covers several areas of scientific investigation, including:
Multi-pathway tissue signaling: Studies examine the combined interaction of all four KLOW components on tissue repair pathway dynamics in laboratory research models.
Inflammatory signaling research: Research investigates KPV-mediated NF-κB pathway modulation in combination with BPC-157 and GHK-Cu inflammatory signaling interactions.
Angiogenesis and vascular biology: Laboratory models explore complementary BPC-157 and TB-500 interactions with VEGF and endothelial signaling pathways.
ECM and cytoskeletal research: Studies evaluate GHK-Cu collagen pathway modulation and TB-500 actin-related cell migration signaling in combined tissue models.
All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.
References
FAQ
Q: What makes KLOW different from individual component peptides?
Q: What makes KLOW different from individual component peptides?
A: KLOW provides all four peptide components — BPC-157, TB-500, KPV, and GHK-Cu — in a single pre-formulated research compound. Each component is batch-tested as part of the complete blend to ≥99% purity, HPLC and mass spectrometry verified, with a COA provided per batch.
Q: Where is BioRhex’s KLOW manufactured?
Q: Where is BioRhex’s KLOW manufactured?
A: All BioRhex compounds, including KLOW, are manufactured in a GMP-compliant facility located in the United States.
Q: What testing does BioRhex conduct on KLOW?
Q: What testing does BioRhex conduct on KLOW?
A: Every batch of KLOW undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.
Q: Is KLOW approved for human use?
Q: Is KLOW approved for human use?
A: No. KLOW is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.
Q: Who should handle this compound?
Q: Who should handle this compound?
A: Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.
Research Use Only
All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. KLOW is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.
RELATED PRODUCTS
AOD9604 (5mg)
BPC-157
BPC-157 + TB-500
CJC (no DAC) + Ipamorelin (10mg)
